KWG: Acute Dose Response of Korean White Ginseng in Metabolic Syndrome or Type 2 Diabetes

Sponsor

Unity Health Toronto (Other)

Overall Status

Completed

CT.gov ID

NCT01699074

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

3.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The study is a Phase-I like double blind randomized placebo controlled crossover design trial. The objective is to assess the dose response relationship on glycemic and vascular effects of an acutely administered Korean White Ginseng (KWG)(Panax C.A. Meyer) in individuals with metabolic syndrome or type 2 diabetes . Twenty seven subjects with Type 2

Diabetes (Key inclusion criteria: HbA1c ≤8.5%)or metabolic syndrome (Key inclusion criteria:

as defined by The US National Cholesterol Education Program Adult Treatment Panel III)will be recruited for the study.

Condition or Disease	Intervention/Treatment	Phase
Type 2 Diabetes Metabolic Syndrome	Dietary Supplement: 1 gram of White Korean Ginseng Dietary Supplement: 3 grams of White Korean Ginseng Dietary Supplement: 6 grams of White Korean Ginseng Dietary Supplement: 3 grams of Wheat Bran Control Dietary Supplement: 500mg of Korean Red Ginseng	Phase 1

Detailed Description

This study hypothesizes that KWG will dose dependently lower postprandial area under the curve compared to negative control, as well as will dose dependently decrease postprandial glycemia. It also assumes that use of KWG will dose dependently decrease aortic and brachial blood pressure, aortic augmentation index, and mean arterial pressure, and improve left ventricular ejection duration(ED) and subendocardial viability ratio (SEVR) compared to control. Finally, it expects to notice an effect on subjective satiety levels and have no significant adverse effects compared to control.

Study Design

Study Type:

Interventional

Actual Enrollment :

30 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

Acute Dose Response Effects of Korean White Ginseng (Panax Ginseng C.A. Meyer) on Cardiovascular Disease Risk Factors in Individuals With Metabolic Syndrome or Type 2 Diabetes

Study Start Date :

May 1, 2013

Actual Primary Completion Date :

Sep 1, 2013

Actual Study Completion Date :

Jan 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 1 gram of White Korean Ginseng 1 gram of White Korean Ginseng	Dietary Supplement: 1 gram of White Korean Ginseng 1 gram of White Korean Ginseng
Experimental: 3 grams of White Korean Ginseng 3 grams of White Korean Ginseng	Dietary Supplement: 3 grams of White Korean Ginseng 3 grams of White Korean Ginseng
Experimental: 6 grams of White Korean Ginseng 6 grams of White Korean Ginseng	Dietary Supplement: 6 grams of White Korean Ginseng 6 grams of White Korean Ginseng
Placebo Comparator: 3 grams of Wheat Bran Control 3 grams of Wheat Bran Control	Dietary Supplement: 3 grams of Wheat Bran Control 3 grams of Wheat Bran Control
Active Comparator: 500mg of Korean Red Ginseng 500mg of Korean Red Ginseng	Dietary Supplement: 500mg of Korean Red Ginseng 500mg of Korean Red Ginseng

Outcome Measures

Primary Outcome Measures

Effect of KWG on vascular and glycemic measures [3 hours]
To evaluate the acute dose response effect of KWG on blood glucose Area under the Curve (AUC) compared to controls in individuals with Metabolic syndrome or Type 2 Diabetes To evaluate the acute effect of KWG treatments on arterial stiffness as measured by aortic augmentation index (AIx)

Secondary Outcome Measures

Effect of KWG on vascular and glycemic measures [4 hours]
To evaluate the acute effect of Korean White ginseng treatments on peak and postprandial glycemia measures.To evaluate the acute effect of KWG treatments on aortic and brachial blood pressure To evaluate the acute effect of KWG treatments on heart rate, mean arterial pressure, left ventricular ejection duration (ED) and subendocardial viability ratio (SEVR) - a surrogate marker of myocardial perfusion

Other Outcome Measures

KWG and satiety [4 hours]
To evaluate the acute effect of KWG treatments on subjective satiety scores to determine any potential effects on appetite control mechanisms compared to controls. Symptoms questionnaire will assess potential adverse effects of treatments (safety)

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Men and women
18-75 years old
BMI 25-35 kg/m2
Presence of type 2 diabetes (as defined by HbA1c ≤8.5%),treatment with diet or oral hypoglycemic medication) OR
Presence of Metabolic Syndrome as defined by The US National Cholesterol -Education Program Adult Treatment Panel III (NCEP III). As per NCEP III criteria, at least three of the following must be present:
central obesity: waist circumference ≥ 102 cm or 40 inches (male), ≥ 88 cm or 36 inches(female)
dyslipidemia: TG ≥ 1.7 mmol/L (150 mg/dl);
dyslipidemia: HDL-C < 40 mg/dL (male), < 50 mg/dL (female) blood pressure ≥ 130/85 mmHg; fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dl)

Exclusion Criteria:

BMI >35 kg/m2
Hypertensive (brachial systolic BP ≥140mmHg and/or diastolic BP ≥90mmHg)
Pregnant women, or those at risk of pregnancy, or breastfeeding at the time of the study.
Women of childbearing age that do not use acceptable method of birth control (ie. abstinence, implants, injectables, oral contraceptives, IUDs etc).
Chronic conditions including: liver disease, cancer, heavy alcohol use, bleeding disorders, history of angina, congestive heart failure, coronary revascularization, peripheral vascular disease, retinopathy, kidney disease or coronary/cerebrovascular event; chronic use of medications including blood-thinners, SSRIs, MAO inhibitors, medications affecting NO synthesis (eg. Viagra)
Allergy or sensitivity to the placebo (wheat bran), ginseng or gelatin used in the capsules.
Use of any ginseng products within three days preceding the study and during the study.
Allergies to Panax species, their constituents or to other members of the Araliaceae family.